Sam Brusco, Associate Editor03.21.22
Israeli portable MRI maker ClearCut Medical appointed Hezi Himelfarb as its CEO, following the company’s transition from development to commercial stage.
Himelfarb was most recently CEO of blood oxygenator developer O2Cure. He was also GM and COO of Microbot Medical, and before that CEO of cryotherapy firm IceCure Medical. He was also CEO of Remon Medical Technologies (sold to Boston Scientific) after spending four years in Medtronic-InStent Israel.
"ClearCut's success to date has been driven by an incredibly strong team. As we prepare for the commercialization of our ClearCoastT intra-operative MRI system, we are happy to be adding world class med-tech executive who will lay the foundation for our future success. Hezi's experience developing and commercializing innovative medical technologies in private and public companies is a perfect fit for ClearCut," chairman Mike Berman told the press. "His proven ability to build value in venture-backed companies and navigate regulatory, reimbursement and early market commercialization environments will be an invaluable asset."
"ClearCut's ClearCoast System is poised to make a major impact on cancer surgery and clinical pathology," noted Himelfarb. "The team has done a phenomenal job developing and clinically testing this important breakthrough in MRI technology form factor, and in establishing strong clinical and strategic relationships that will be the basis for global adoption starting with the European launch this year. It is exciting to join such a talented team."
Himelfarb was most recently CEO of blood oxygenator developer O2Cure. He was also GM and COO of Microbot Medical, and before that CEO of cryotherapy firm IceCure Medical. He was also CEO of Remon Medical Technologies (sold to Boston Scientific) after spending four years in Medtronic-InStent Israel.
"ClearCut's success to date has been driven by an incredibly strong team. As we prepare for the commercialization of our ClearCoastT intra-operative MRI system, we are happy to be adding world class med-tech executive who will lay the foundation for our future success. Hezi's experience developing and commercializing innovative medical technologies in private and public companies is a perfect fit for ClearCut," chairman Mike Berman told the press. "His proven ability to build value in venture-backed companies and navigate regulatory, reimbursement and early market commercialization environments will be an invaluable asset."
"ClearCut's ClearCoast System is poised to make a major impact on cancer surgery and clinical pathology," noted Himelfarb. "The team has done a phenomenal job developing and clinically testing this important breakthrough in MRI technology form factor, and in establishing strong clinical and strategic relationships that will be the basis for global adoption starting with the European launch this year. It is exciting to join such a talented team."